Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Cambridge, MA, on 26-28 September, 2025. Esteemed experts gathered to discuss the latest research findings in NHL and strategies to enhance patient outcomes. iwNHL 2025 was supported by AbbVie (Platinum Supporter), Genentech (Platinum Supporter), Genmab (Platinum Supporter), Johnson & Johnson (Platinum Supporter), AstraZeneca (Gold Supporter), BMS (Gold Supporter), Kite Pharma (Gold Supporter), BeOne Medicines (Silver Supporter), Caribou Biosciences (Silver Supporter), ADC Therapeutics (Bronze Supporter), Novartis (Bronze Supporter), Nurix (Bronze Supporter), Regeneron (Bronze Supporter) and Secura Bio (Bronze Supporter). Supporters of the workshop have no influence over the production of content.
iwNHL 2025
The 22nd International Workshop on Non-Hodgkin Lymphoma
26–28 September 2025 | Cambridge, MA
The 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Cambridge, MA, on 26-28 September, 2025. Esteemed experts gathered to discuss the latest research findings in NHL and strategies to enhance patient outcomes. iwNHL 2025 was supported by AbbVie (Platinum Supporter), Genentech (Platinum Supporter), Genmab (Platinum Supporter), Johnson & Johnson (Platinum Supporter), AstraZeneca (Gold Supporter), BMS (Gold Supporter), Kite Pharma (Gold Supporter), BeOne Medicines (Silver Supporter), Caribou Biosciences (Silver Supporter), ADC Therapeutics (Bronze Supporter), Novartis (Bronze Supporter), Nurix (Bronze Supporter), Regeneron (Bronze Supporter) and Secura Bio (Bronze Supporter). Supporters of the workshop have no influence over the production of content.
Roundtable discussions & expert interviews
View all
Session 1: T-cell Leukemia/Lymphoma
Update on consensus for the next classification of hematological malignancies
Laurence de Leval Lausanne University Hospital, Lausanne, Switzerland
Pre-clinical models for precision therapy in TCLs
François Lemonnier Paris-East Créteil University, Paris, France
PETAL Consortium: Leveraging Multimodal Global Data and Artificial Intelligence
Salvia Jain Massachusetts General Hospital, Boston, MA, United States
Aggressive T-cell lymphoma in refractory patients
Francine Foss Yale School of Medicine, New Haven, CT, United States
Session 2: MCL
Evolution of mantle cell lymphoma: from conception to the current reality
Elaine Jaffe National Cancer Institute, Bethesda, MD, United States
Frontline therapy for MCL – which patient needs which initial regimen?
Michael Wang The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Consolidation after frontline therapy – is autologous stem cell transplantation for MCL a thing of the past?
Ann LaCasce Dana-Farber Cancer Institute, Boston, MA, United States
Small molecule inhibitors for relapsed MCL – one at a time or all together?
Tycel Phillips City of Hope, Duarte, CA, United States
Novel therapies (Part I)
McAbs and ADC Combinations: Brentuximab combinations
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Trial recruitment demographics – what is considered representative
Simon Rule University of Plymouth, Plymouth, United Kingdom
Loncastuximab combinations
Juan Pablo Alderuccio University of Miami, Miami, FL, United States
Polatuzumab combinations
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Special topic: Hodgkin’s lymphoma
Beyond 2nd line
Alex Herrera City of Hope, Duarte, CA, United States
HL in older adults
Sarah Rutherford Weill Cornell University, New York, NY, United States
1st line therapy in AYA patients with Hodgkin lymphoma
Ann LaCasce Dana-Farber Cancer Institute, Boston, MA, United States
Bispecific antibodies in 1st and 2nd line treatment of FL and LBCL
Mosunetuzumab
Elizabeth Budde City of Hope, Duarte, CA, United States
Epcoritamab combinations
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Glofitamab combinations
Martin Hutchings Copenhagen University Hospital, Copenhagen, Denmark
Plamotamab combinations
Tycel Phillips City of Hope, Duarte, CA, United States
AZD0486
Sameh Gaballa Moffitt Cancer Center, Tampa, FL, United States
Future perspectives with bi-and trispecific antibodies
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Novel therapies (Part II)
ibrutinib
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Pirtobrutinib
Michael Wang The University of Texas MD Anderson Cancer Center, Houston, TX, United States
BTK degaraders: zelebrudomide(NX-2127) & bexobrutideg (NX-5948)
Alexey Danilov City of Hope, Duarte, CA, United States
BTK & BCL-2 inhibitors: novel therapies for waldenstrom’s macroglobulinemia
Steve Treon Dana-Farber Cancer Institute, Boston, MA, United States
Expanding the CAR platform for NHL
Real World Data
Liso-cel for DLBCL
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Axi-cel
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Tisa-cel
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Future perspectives – where do we go from here?
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Rapcabtagene
Connor Johnson Massachusetts General Hospital, Boston, MA, United States
Multi-targeted and in vivo CARs
Tanya Siddiqi City of Hope, Duarte, CA, United States
Roundtable discussions & expert interviews
View all
